Cytoreductive Nephrectomy After Immunotherapy
Author Information
Author(s): Laura E. Davis, Adam Calaway, Eric A. Singer, Shawn Dason
Primary Institution: Case Western Reserve University Hospitals Urology Institute, Cleveland, OH, USA
Hypothesis
What is the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma following immunotherapy?
Conclusion
Cytoreductive nephrectomy following immunotherapy is safe and beneficial in appropriately selected patients.
Supporting Evidence
- Patients treated with cytoreductive nephrectomy and interferon had superior outcomes compared to those treated with interferon alone.
- The CARMENA trial showed non-inferiority of sunitinib alone compared to cytoreductive nephrectomy plus sunitinib.
- Upfront cytoreductive nephrectomy was associated with improved overall survival in patients receiving immune checkpoint inhibitors.
Takeaway
This study looks at how surgery can help patients with kidney cancer that has spread after they have received immunotherapy. It finds that surgery can be a good option for some patients.
Methodology
The review discusses historical and current treatments for metastatic renal cell carcinoma, focusing on cytoreductive nephrectomy and its outcomes in relation to immunotherapy.
Potential Biases
The observational nature of many studies may introduce confounding factors.
Limitations
Many supporting trials are retrospective and may be subject to selection bias.
Participant Demographics
Patients with metastatic renal cell carcinoma, specifics not detailed.
Statistical Information
P-Value
p=0.05
Confidence Interval
95% CI 0.36–0.97
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website